CD274 and neoplasm: The results of subgroup analysis by varying the HR of OS showed that the following subgroups were associated with positive ICER and > 50% probability to be cost-effective: patients older than 65 years old, patients with ECOG performance status score equals to 1, patients with disease stage IIIB/IIIC, and patients with PD-L1 tumor proportion score ≤ 1%.